Royce & Associates’s Tandem Diabetes Care TNDM Stock Holding History

Royce & Associates’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.4M	Buy	696,590 +46,340	+7%	+$1.01M	0.13%	256
2025 Q4	$14.3M	Buy	650,250 +140,250	+28%	+$2.53M	0.14%	214
2025 Q3	$6.19M	Buy	+510,000	New	+$6.9M	0.06%	424
2021 Q3	–	Sell	-78,286	Closed	-$7.63M	–	1015
2021 Q2	$7.63M	Buy	78,286 +9,900	+14%	+$883K	0.05%	505
2021 Q1	$6.04M	Buy	68,386 +1,300	+2%	+$121K	0.04%	564
2020 Q4	$6.42M	Buy	67,086 +31,800	+90%	+$3.28M	0.05%	498
2020 Q3	$4M	Buy	35,286 +11,700	+50%	+$1.23M	0.04%	518
2020 Q2	$2.33M	Sell	23,586 -14,000	-37%	-$1.12M	0.03%	635
2020 Q1	$2.42M	Sell	37,586 -29,500	-44%	-$2.07M	0.03%	550
2019 Q4	$4M	Buy	67,086 +16,586	+33%	+$1.02M	0.04%	544
2019 Q3	$2.98M	Buy	+50,500	New	+$3.22M	0.03%	611

Other funds holding TNDM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royce & Associates's TNDM Position: Q1 2026 in Review

Royce & Associates increased its Tandem Diabetes Care (TNDM) stake by 7.1% in Q1 2026, buying an estimated $1.01M and bringing the position to 696,590 shares worth $13.4M. The position accounts for 0.13% of the portfolio, ranked #256.

Royce & Associates first reported a position in TNDM in Q3 2019 and has held it in 11 quarters since. The position peaked at $14.3M in Q4 2025. 272 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.

Royce & Associates held 696,590 shares of Tandem Diabetes Care worth $13.4M as of Q1 2026.
Royce & Associates bought 46,340 Tandem Diabetes Care shares in Q1 2026, an estimated $1.01M.
Tandem Diabetes Care made up 0.13% of Royce & Associates's portfolio in Q1 2026, its #256 holding.
Royce & Associates first reported a position in Tandem Diabetes Care in Q3 2019 and has held it in 11 quarters since.
Royce & Associates's Tandem Diabetes Care position peaked at $14.3M in Q4 2025.
272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.